Clinical Trials
Current ACCT trial activity includes:
A Phase I Study of LBH589 in Paediatric Patients with Refractory Solid Tumours Including CNS Tumours.
An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Paediatric Patients With Relapsed or Refractory Acute Leukaemia.
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy.
A Phase I/Phase 2 Study of CP-751,871 in Patients With Relapsed and/or Refractory Ewing’s Sarcoma Family of Tumours.
.
Upcoming ACCT trials include:
A Phase1/2 Study of Valproate in Combination with Interferon alpha in Relapsed, Recurrent or Progressive Neuroblastoma.
A preclinical study of the effects of the pan-Her inhibitor PF-00299804 (PF) alone, or in combination with irradiation and other chemotherapeutic agents, on the growth of CNS-PNET cell lines and human neural stem cells.
A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) subjects.
ACCT also contributes to the conduct of Children’s Oncology Group trials undertaken at children’s cancer centres in Australia.